J&J’s new part­ner­ship with Elek­trofi; Enyo rais­es €39M; Ar­row­head­'s $450M of­fer­ing

Plus, news about TC Bio­Pharm, Bio­Cen­triq, 4D Mol­e­c­u­lar and Ar­bor Biotech­nolo­gies, and Long­board Phar­ma­ceu­ti­cals:

John­son & John­son teams up with Elek­trofi: The Boston biotech will work with J&J’s Janssen Biotech to cre­ate an at-home self-ad­min­is­tered un­der-the-skin ver­sion of a “lead on­col­o­gy as­set.” Elek­trofi snagged an up­front pay­ment of $18 mil­lion and could re­ceive $155 mil­lion or more in mile­stones per tar­get in the mul­ti-tar­get pact. — Kyle LaHu­cik

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.